Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.
Int J Clin OncolJul 23, 2026 (epub)
Chika Nitani, Junichi Hara, Hiroshi Kawamoto et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the efficacy of an alternative immunotherapy regimen (G-CSF/teceleukin) versus a standard regimen (GM-CSF/aldesleukin/isotretinoin) in children with high-risk neuroblastoma. Among 35 patients, the 2-year event-free survival (EFS) was 80.8% for the alternative regimen compared to 62.3% for the standard regimen, indicating comparable efficacy.
Key findings
- The 2-year event-free survival (EFS) was 80.8% for regimen A and 62.3% for regimen B.
- Overall survival (OS) rates were 93.8% for regimen A and 100.0% for regimen B.
- The hazard ratio for EFS comparing regimen A to B was 0.494.
Why it matters
Understanding the efficacy of alternative immunotherapy regimens is crucial, especially in regions where standard treatments are unavailable. This study provides insights into potential treatment options for high-risk neuroblastoma in children.